Cost-effectiveness of Treatment for Hepatitis C in an Urban Cohort Co-infected with HIV

American Journal of Medicine

Volumn 120, Issue 3, 2007, Pages 272-279

  Campos, Nicole G ^a   Salomon, Joshua A ^b   Servoss, Julie C ^c   Nunes, David P ^d   Samet, Jeffrey H ^d   Freedberg, Kenneth A ^b,c   Goldie, Sue J ^b  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BOSTON MEDICAL CENTER   (United States)

Author keywords

Clinical guidelines; Cost effectiveness; Hepatitis C virus (HCV); Human immunodeficiency virus (HIV); Peginterferon alfa and ribavirin; Treatment eligibility

Indexed keywords

ALPHA2A INTERFERON; ANTIRETROVIRUS AGENT; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; COMPUTER MODEL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG EFFICACY; ESOPHAGUS VARICES BLEEDING; FEMALE; HEALTH CARE COST; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SURVIVAL; UNITED STATES; URBAN POPULATION; VIRUS HEPATITIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; COHORT STUDIES; COST OF ILLNESS; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MARKOV CHAINS; MIDDLE AGED; RIBAVIRIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES; URBAN HEALTH;

EID: 33847413985     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2006.06.036     Document Type: Article

References (38)

1. U.S. Department of Health and Human Services. HIV/AIDS Statistics, NIAID Facts and Figures (2004) July
2. Sulkowski M.S., Mast E.E., Seeff L.B., and Thomas D.L. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis 30 Suppl 1 (2000) S77-S84
3. Graham C.S., Baden L.R., Yu E., et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 33 (2001) 562-569
4. Bica I., McGovern B., Dhar R., et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 32 (2001) 492-497
5. Greub G., Ledergerber B., Battegay M., et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 356 (2000) 1800-1805
6. Anderson K.B., Guest J.L., and Rimland D. Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. Clin Infect Dis 39 (2004) 1507-1513
7. Sulkowski M.S., Moore R.D., Mehta S.H., Chaisson R.E., and Thomas D.L. Hepatitis C and progression of HIV disease. JAMA 288 (2002) 199-206
8. Hadziyannis S.J., Sette Jr. H., Morgan T.R., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
9. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
10. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
11. Torriani F.J., Rodriguez-Torres M., Rockstroh J.K., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 351 (2004) 438-450
12. Carrat F., Bani-Sadr F., Pol S., et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 292 (2004) 2839-2848
13. Chung R.T., Andersen J., Volberding P., et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 351 (2004) 451-459
14. Laguno M., Murillas J., Blanco J.L., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 18 (2004) F27-F36
15. U.S. Food and Drug Administration Center for Drug Evaluation and Research. CDER Fast Track Products Approved Since 1998 Through September 30, 2005. Available at: http://www.fda.gov/cder/rdmt/internetftap.htm. Accessed January 19, 2006.
16. Kuehne F.C., Bethe U., Freedberg K., and Goldie S.J. Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness. Arch Intern Med 162 (2002) 2545-2556
17. Salomon J.A., Weinstein M.C., Hammitt J.K., and Goldie S.J. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 290 (2003) 228-237
18. Fleming C.A., Craven D.E., Thornton D., Tumilty S., and Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 36 (2003) 97-100
19. Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. Cost-effectiveness in Health and Medicine (1996), Oxford University Press, New York, NY
20. Lau D.T., Kleiner D.E., Ghany M.G., Park Y., Schmid P., and Hoofnagle J.H. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 28 (1998) 1121-1127
21. Feld J.J., and Hoofnagle J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436 (2005) 967-972
22. Marcellin P., Boyer N., Gervais A., et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 127 (1997) 875-881
23. Arima M., Terao H., Kashima K., Arita T., Nasu M., and Nishizono A. Regression of liver fibrosis in cases of chronic liver disease type C: quantitative evaluation by using computed image analysis. Intern Med 43 (2004) 902-910
24. Maida I., Nunez M., Gonzalez-Lahoz J., and Soriano V. Liver transplantation in HIV-HCV coinfected candidates: what is the most appropriate time for evaluation?. AIDS Res Hum Retroviruses 21 (2005) 599-601
25. Moreno S., Fortun J., Quereda C., et al. Liver transplantation in HIV-infected recipients. Liver Transpl 11 (2005) 76-81
26. Salomon J.A., Weinstein M.C., Hammitt J.K., and Goldie S.J. Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol 156 (2002) 761-773
27. Martinez-Sierra C., Arizcorreta A., Diaz F., et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 36 (2003) 491-498
28. Mohsen A.H., Easterbrook P.J., Taylor C., et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 52 (2003) 1035-1040
29. Benhamou Y., Bochet M., Di Martino V., et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 30 (1999) 1054-1058
30. Marine-Barjoan E., Saint-Paul M.C., Pradier C., et al. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients. AIDS 18 (2004) 2163-2170
31. Bennett W.G., Inoue Y., Beck J.R., Wong J.B., Pauker S.G., and Davis G.L. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 127 (1997) 855-865
32. Freedberg K.A., Scharfstein J.A., Seage III G.R., et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA 279 (1998) 130-136
33. Di Martino V., Rufat P., Boyer N., et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 34 (2001) 1193-1199
34. Red Book 2004: Pharmacy's Fundamental Reference (2004), Thomson Healthcare, Stamford, CT
35. Wong J.B., Poynard T., Ling M.H., Albrecht J.K., Pauker S.G., and International Hepatitis Interventional Therapy Group. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. Am J Gastroenterol 95 (2000) 1524-1530
36. Sanders G.D., Bayoumi A.M., Sundaram V., et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 352 (2005) 570-585
37. Bozzette S.A., Joyce G., McCaffrey D.F., et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med 344 (2001) 817-823
38. Fleming C.A., Tumilty S., Murray J.E., and Nunes D. Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: need for team care. Clin Infect Dis 40 Suppl 5 (2005) S349-S354